4/16/2021

Meperidine Hydrochloride Injection

Products Affected - Description

- Demerol injection, Pfizer, 100 mg/mL, 20 mL multiple dose vial, 1 count, NDC 00409-1201-20 - discontinued
- Demerol injection, Pfizer, 50 mg/mL, 2 mL ampule, 25 count, NDC 00409-1255-02

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Pfizer has Demerol injection on shortage due to manufacturing delays. Pfizer discontinued Demerol 50 mg/mL 0.5 mL, 1 mL ampules, and 1.5 mL ampules and 100 mg/mL 1 mL ampules in July 2020. Pfizer discontinued Demerol 100 mg/mL 20 mL vials in April 2021.
- ICU Medical discontinued meperidine 30 mL PCA vials.

Available Products

- Demerol injection, Pfizer, 100 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1180-69
- Demerol injection, Pfizer, 25 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1176-30
- Demerol injection, Pfizer, 50 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1178-30
- Demerol injection, Pfizer, 50 mg/mL, 30 mL multiple dose vial, 1 count, NDC 00409-1181-30
- Demerol injection, Pfizer, 75 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1179-30
- Meperidine injection, Hikma, 100 mg/mL, 1 mL vial, 25 count, NDC 00641-6054-25
- Meperidine injection, Hikma, 25 mg/mL, 1 mL vial, 25 count, NDC 00641-6052-25
- Meperidine injection, Hikma, 50 mg/mL, 1 mL vial, 25 count, NDC 00641-6053-25

Estimated Resupply Dates

- Pfizer has Demerol 50 mg/mL 2 mL ampules on a long-term back order and the company estimates a release date of February 2023.
- All other marketed presentations are available.

Updated

Updated April 16, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 19, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.